Licence agreement concerning inclusion of doctoralSemisynthetic Glycopeptide Antibiotics • October 19th, 2022
The rise of multi-drug resistant (MDR) bacteria, paired with the decrease in discovery of novel antibiotics, is a major threat to world health. A recent study reported that 1.27 million deaths were directly attributable to antimicrobial resistance (AMR) in 2019, with an additional 4.95 million deaths estimated to be associated with AMR.1 The Gram- positive pathogens methicillin-resistant Staphylococcus aureus (MRSA) and S. pneumonia accounted for 0.5 million deaths alone in 2019.1 Among the therapeutic options available for treatment of such Gram-positive infections, the glycopeptide antibiotics, typified by vancomycin, have been a mainstay for many years.2 While the glycopeptides are among the most potent anti-Gram-positive agents available, resistance to these antibiotics is also widespread, spurring the continued search for new semisynthetic analogues with enhanced activities and safety profiles. To date, a number of reviews have been published on the broad topic of the glycopeptide
